Prostate Cancer

The FDA has approved abiraterone acetate in combination with prednisone prior to chemotherapy for the treatment of men with metastatic castration-resistant prostate cancer.

Single-agent cabozantinib has shown promising activity in early-stage trials involving heavily pretreated patients with metastatic castration-resistant prostate cancer. Researchers are now attempting to find the optimal dose of the drug in this patient population.

Mary-Ellen Taplin, MD, from the Dana-Farber Cancer Institute, discusses unique mechanism of action of enzalutamide in metastatic castration-resistant prostate cancer.

Enzalutamide significantly delayed the time to first SRE and significantly improved pain and QOL compared with placebo in men with mCRPC who had received prior docetaxel.

A research team has discovered 12 genetic markers associated with the development of erectile dysfunction in prostate cancer patients treated with radiation.

A deeper understanding of androgen receptor signaling in castration-resistant prostate cancer has created an opportunity to deliver more effective therapies earlier in the treatment timeline.

William K. Oh, MD, from the Tisch Cancer Institute, discusses strategies for sequencing the new therapies that have been approved for treating castration-resistant prostate cancer.

Men who take the dietary antioxidant beta-carotene while they are undergoing radiation therapy for prostate cancer do not have an increased risk of prostate cancer death or metastases.